Moderna, Inc. (MRNA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 143.38 |
| Open | 143.07 |
| Bid | 135.45 x 1100 |
| Ask | 136.00 x 1000 |
| Day's Range | 131.39 - 144.77 |
| 52 Week Range | 119.01 - 497.49 |
| Volume | |
| Avg. Volume | 7,157,155 |
| Market Cap | 55.243B |
| Beta (5Y Monthly) | 1.54 |
| PE Ratio (TTM) | 8.16 |
| EPS (TTM) | 16.69 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 230.27 |
- Motley Fool
3 Stocks That Could Make You a Fortune Over the Next 10 Years
Here's why they picked Exelixis (NASDAQ: EXEL), Moderna (NASDAQ: MRNA), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Exelixis): If you're looking to hit a home run with an investment, it's important to look for a balance of a modest valuation and promising growth. One underrated stock that possesses all these features is cancer-fighting company Exelixis, which has a market cap of around $5.4 billion.
- Motley Fool
Better Buy: Moderna or Novavax?
Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) are no longer big winners for investors. Let's first address the uncertainties for Moderna. There are questions about the high number of side effects of its experimental influenza vaccine.
- Motley Fool
Why Pfizer Stock Is Rising Today While Moderna and Novavax Are Sliding
Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.
